32 results about "Stem cell population" patented technology

Therefore, this disclosure provides a genetically engineered mesenchymal stem cell (MSC) population, including an expression vector containing the Akt or HGF gene and the PD-L1 gene. It also provides a method for synergistically improving the survival status and immunomodulatory capacity of mesenchymal stem cells or enhancing their proliferation, including transfecting mesenchymal stem cells with the Akt or HGF gene and the PD-L1 gene; and a method for preventing, improving, and / or treating ischemic conditions, enhancing neurogenesis, or reducing neuronal death, including administering an effective amount of the genetically engineered mesenchymal stem cell population of this disclosure to individuals in need.

Genetically modified zebrafish, in which mutation combinations frequently identified in human AML are stably expressed in the stem cell population of the fish, are provided. The combination of mutations result in morphologic, cytochemical and molecular changes of its blood cells that are remarkably similar to those in human AML. The zebrafish model provides a foundation for the study of AML initiation and progression and a high throughput in vivo drug screening platform to identify personalized therapies for AML based on specific mutation combinations. The method of drug screening includes contacting embryos or adult fish containing mutations as disclosed herein, with a test agent, at test concentrations and test intervals to determine the therapeutic effect if any, of the test agent.

To provide safe and high-performance stem cells appropriate for clinical application, and a method for producing the stem cells.SOLUTION: Provided are a stem cell population derived from human deciduous tooth dental pulp, wherein 90% or more of the stem cell population is characterized by being CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and a method for producing a stem cell population derived from human deciduous tooth dental pulp, the method comprising a step of culturing cells isolated from human deciduous tooth dental pulp in a medium that does not contain FBS (fetal bovine serum) in the presence of human platelet lysate (hPL).SELECTED DRAWING: None

The invention belongs to a cell culture technology in the field of biomedicine, and particularly relates to a liver organoid for traditional Chinese medicine screening and toxicity assessment and a construction method and application thereof. The construction method comprises the following steps: carrying out plane multiplication culture on pluripotent stem cells, then digesting and subculturing, and repeating to obtain a cell culture medium; a pluripotent stem cell group which is uniform in cell morphology and free of spontaneous differentiation is obtained; performing two-dimensional plane directional induction on the pluripotent stem cell population to enable cells to synchronously and uniformly receive differentiation signals to obtain hepatogenic mother cells; culturing the obtained hepatic mastocytes by using a culture medium E under a three-dimensional suspension condition to promote the specificity and balling of the hepatic lineage; the culture medium E is an Advanced DMEM / F12 which comprises 1 to 5 [mu] M of RA, 2 to 10 [mu] M of Y-27632, 0.5 to 1 [mu] M of beta-nicotinamide mononucleotide, 5 to 10 [mu] M of senkyunolide A, B27 and N2; and then replacing the culture medium to further mature and functionalize the hepatocytes to obtain the liver organoid, and the obtained liver organoid has high stability, high uniformity, good survival rate and mature hepatocyte functions.

To clarify the heterogeneous composition of mesenchymal stromal / stem cells (MSCs) and identify functional subpopulations of MSCs.SOLUTION: Provided is a method for identifying functional cell subpopulations in a cell population of MSCs, comprising: performing omics analysis of the cell population of MSCs at the single cell level; and clustering the cell population of MSCs based on the results of the analysis to classify it into cell subpopulations.SELECTED DRAWING: None

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

The present invention provides methods and systems for enhanced production and / or secretion of extracellular vesicles from at least one three-dimensional porous scaffold having a population of stem cells cultured thereon, utilizing various shear stress conditions on a variety of stem cells.

The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

This method for estimating the therapeutic effect of stem cell transplantation comprises: a step (S11) for acquiring a plurality of cell images in which a stem cell group in culture is imaged at a plurality of predetermined time points within a cell culturing period for stem cell transplantation for regenerative medicine purposes; a step (S12) for identifying stem cell regions respectively in the plurality of cell images; a step (S13) for acquiring, on the basis of the identified stem cell regions, a plurality of types of index values associated with the stem cell group with respect to each of the plurality of cell images; and a step (S14) for estimating, before the transplantation of the stem cell group obtained by the cell culturing, the therapeutic effect of the transplantation of the stem cell group on the basis of the acquired plurality of types of index values. The plurality of types of index values acquired in step (S13) include a plurality of types of index values associated with the morphologies of the stem cells.

The disclosure is drawn to an isolated somatic stem cell population including somatic stem cells that are PD-L1+ and methods of using the isolated somatic stem cell population to modulate an immune response.

The present invention provides a method for identifying functional cell subpopulations in an MSCs cell population, the method comprising performing omics analysis of an MSCs cell population at the single cell level and clustering the MSCs cell population based on the results of the analysis to classify the cell population into cell subpopulations.

This invention relates to a method for evaluating the wound-healing efficacy of mesenchymal stem cell (MSC) populations. Furthermore, this invention relates to a method for selecting MSCs for generating stem cell populations under cGMP conditions, and a method for selecting MSC populations for generating stem cell populations for subsequent drug administration. Additionally, this invention relates to a method for selecting MSC populations for generating a master cell bank, and a method for identifying tissues suitable as starting materials for generating MSC populations for drug use. The method includes measuring the levels of at least two proteins selected from angiopoietin-1 (Ang-1), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), and hepatocyte growth factor (HGF) secreted by MSCs into the culture medium.

The present invention relates to a method of inducing or improving wound healing properties of a population of mesenchymal stem cells, the method comprising culturing the population of mesenchymal stem cells in a culture medium comprising DMEM (Dulbecco Modified Eagle Medium), F12 (Hamm F12 Medium), M171 (Medium 171) and FBS (fetal calf serum). The present invention also relates to a population of mesenchymal stem cells wherein at least about 90% or more of the cells of the population of stem cells express each of the following markers: CD73, CD90 and CD105 and lack the expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of the mesenchymal stem cell population.

Provided are methods to increase the nephron yield and control over nephron locations in kidney organoids and kidney replacement tissues; the methods achieve spatiotemporal control over the mechanical microenvironment to engineer favorable environments for nephron formation within kidney organoids. This engineered control can be created using microdevices that impose mechanical stress at defined intervals synchronized with cyclical nephron development in vivo, agonists / antagonists of tension-generating biochemical pathways in whole organoids or cells, optogenetic control over tension in stem cell collectives, and / or cell-cell junction mediated transfer of mechanical information between cells, or similar approaches.

An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying the expression of the cell adhesion molecule in the population of isolated mammalian stem cells to decrease or knockout expression of the cell adhesion molecule and provide the population of hypoimmune mammalian cells. The population of isolated mammalian stem cells can be pluripotent stem cells, or embryonic stem cells, and can be human or non-human stem cells.

The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.

The present disclosure relates to a compound of formula (I)where R1 is as defined herein. The compound of formula I is an inhibitor of the dephosphorylation of phosphorylated elF2α. The phosphorylation of elF2α affects the quiescence and self renewal properties of stem cells such as muscle stem cells. The compound of formula (I) can thus be used to expand stem cells populations and treat degenerative diseases that have a quiescence regulation affected or mediated by the phosphorylation of elF2α.

Certain populations of small cells present in adult human tissue can undergo activation / development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation / development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

Culture media and methods for the expansion and differentiation of stem cell populations and for obtaining organoids. Expanded cell populations and organoids obtainable by the methods of the invention and their use in drug screening, toxicity testing, and regenerative medicine.

A method of producing a population of mature human pluripotent stem cell-derived sensory neurons (hPSC-SNs) expressing a target gene associated with at least one of nociceptive pain, chronic pain, pruriception and a nociceptive- or pruriceptive- mediated condition, the method comprising introducing into a population of human pluripotent stem cells (hPSCs) a composition comprising at least one site-directed nuclease targeting a site within the target gene, and at least one nucleic acid comprising a nucleotide sequence encoding at least one screenable, selectable marker that is flanked by (i) a nucleotide sequence homologous with a region located upstream of the target site within the target gene and (ii) a nucleotide sequence homologous with a region located downstream of the target site within the target gene, wherein the target site is located downstream of the open reading frame of the target gene, and wherein the site-directed nuclease cleaves the target site of the target gene and the nucleic acid encoding the screenable, selectable marker is inserted at the target site; covering said population of hPSCs under an extracellular matrix comprising at least one neuronal differentiation driver to produce a sensory committed neural crest population; contacting said sensory committed neural crest population with at least one neuronal differentiation driver and at least one neurotrophic factor to produce a population of early sensory neurons (SNs); and contacting said population of early SNs with at least one neurotrophic factor to produce a population of mature hPSC-SNs expressing at least one of SN marker or one pan neuronal marker; isolating the cells expressing the at least one screenable, selectable marker, wherein said population of mature hPSC-SNs expressed said one target gene associated with nociceptive pain, chronic pain, pruriception a nociceptive- or pruriceptive- mediated condition, and wherein said population of mature hPSC-SNs responds to a nociceptive and pruriceptive stimulus.

This invention provides a method for differentiating SAN-like cells from pluripotent stem cells in vitro. The method for differentiating SAN-like cells from pluripotent stem cells in vitro includes S1, providing a population of pluripotent stem cells; S2, performing a first contact culture on the pluripotent stem cell population to obtain mesodermal cells; S3, performing a second contact culture on the mesodermal cells to obtain pSHF cells; and S4, performing a third contact culture on the pSHF cells to obtain SAN-like cells. This invention solves at least one of the following problems in the prior art: the induction efficiency of sinoatrial node (SAN)-like cells from pluripotent stem cells is generally low, usually only 30%–50%; and the differentiation cycle is long, the operation steps are cumbersome, and a variety of small molecule additives are required. In addition, the differentiation products contain a large number of NKX2.5 positive atrial or ventricular myocytes, resulting in insufficient purity, which still requires further cell separation and purification.

The invention belongs to the technical field of cell biology, and particularly relates to a separation method of skeleton-derived hematopoietic stem cells applicable across animal categories. The method provided by the invention is used for sorting based on the capability of the cells to retain nucleic acid dye, and is particularly suitable for separating invertebrate stem cells lacking specific antibodies. The BSCS living cell nucleic acid dye used in the invention can emit blue fluorescence under the excitation of ultraviolet light, and the stem cells highly express ABC transporter protein, so that compared with other cell types, the BSCS living cell nucleic acid dye has stronger dye excretion capability. Therefore, when the mixed cell suspension dyed for a long time is subjected to flow cytometry, the stem cell population can show lower fluorescence intensity in the V-450 channel. The low toxicity of the BSCS ensures the minimum damage to the cells; the dependence of a traditional method on a specific surface antibody is broken through; the method has wide applicability and can be used for separation and purification of most invertebrate stem cell groups lacking specific markers.

The present invention relates, for example, to a stem cell population derived from human deciduous dental pulp, the stem cell population being characterized in that 90% or more of the stem cell population is CD117-negative, CD73-positive, CD90-positive, and CD105-positive, and to a method for producing a stem cell population derived from human deciduous dental pulp, comprising the step of culturing cells isolated from the human deciduous dental pulp in a medium free of FBS (fetal bovine serum) in the presence of a human platelet lysate (hPL). The present invention also relates to an agent for preventing or treating cerebral palsy, comprising dental pulp stem cells, wherein the prevention or treatment agent is administered to a subject with symptoms of cerebral palsy.

Disclosed are compositions including a population of human enteric neural stem cells (ENSCs), wherein the population comprises at least one of a cell expressing nerve growth factor receptor (NGFR), a cell expressing integrin alpha 6 (ITGA6), a cell expressing L1 cell adhesion molecule (L1CAM), a cell that expresses proteolipid protein 1 (PLP1), and / or a cell that expresses paired-like homeobox 2B (PHOX2B), methods of producing the compositions, and their uses.

To provide a method for producing retinal pigment epithelial cells.SOLUTION: A method of producing retinal pigment epithelium (RPE) cells, comprising the steps of: (a) culturing a cell population of undifferentiated human pluripotent stem cells on an adherent surface selected from the group consisting of laminin, fibronectin, vitronectin, collagen I and collagen IV in a medium comprising nicotinamide as a differentiation-inducing agent and lacking activin A under feeder cell-free conditions to obtain differentiated cells; (b) culturing the differentiated cells on the adherent surface in a medium comprising nicotinamide and one or more members of the TGF β superfamily selected from the group consisting of TGF β 1, TGF β 3, and activin A to obtain RPE cells, wherein at least 50% of the cells in the population of cells are Oct4 + TRA-1-60 +.SELECTED DRAWING: Figure 1

The present disclosure provides genomically stabilized pluripotent stem cell (PSC) populations with reduced tumorigenic potential and methods of their production, maintenance, and use, e.g., in the production of differentiated cells for cell-based therapies. The disclosure further provides methods of identifying genomically stabilized PSCs, useful, e.g., in the processes of cell banking and manufacturing of cell therapies.

To provide genetically modified cells and uses thereof.SOLUTION: The present invention generally relates to a population of stem cells (e.g., iPSCs or HSCs) comprising a T cell receptor and a nucleic acid encoding a chimeric antigen receptor directed to a plurality of distinct antigenic determinants, e.g., two distinct tumor antigenic determinants. The present invention is also directed to a population of T cells co-expressing a T cell receptor and a chimeric antigen receptor directed to multiple distinct antigenic determinants, such as two distinct tumor antigenic determinants. The cells of the invention may be derived from selected donors whose HLA type matches a significant sector of the population, and are useful in a variety of applications, particularly in the context of therapeutic treatment of neoplastic conditions.SELECTED DRAWING: None